U.K. medical regulators have approved a “world-first” gene therapy that aims to cure two blood disorders: sickle cell disease (SCD) and transfusion-dependent β-thalassemia. They are the first regulatory body to approve the treatment.

Eli Lilly and Company (NYSE: LLY) and Sigilon Therapeutics, Inc. (Nasdaq: SGTX) today announced a definitive agreement for Lilly to acquire Sigilon, a biopharmaceutical company that seeks to develop functional cures for patients with a broad range of acute and chronic diseases.

GenScript Biotech, a preeminent global provider of life sciences services, and Boan Biotech, an integrated biopharmaceutical company specializing in the development, manufacturing and commercialization of biologics, announced a collaboration for the development and production of GenCircleTM dsDNA, a small circular double-stranded DNA vector without resistance markers, a key ingredient in gene and cell therapy.

Alzheimer's disease (AD) is a common neurodegenerative disease that affects the cognitive and memory abilities of the brain.

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors